“We are mitigating these by price increases to some extent,” the company’s management said in an investor presentation.
“We are confident about the demand environment going into the new year as we have unique value propositions that would continue to drive growth,” it said.
The company’s fourth quarter FY2026 net profit increased 6.65 per cent to Rs 16.19 crore from Rs 15.18 crore in the same period last year.
It included a one-time charge of Rs 7.6 crore related to a legal case involving lease rent and Rs. 12.5 crore toward new labour code.
Net sales increased 10.6 per cent to Rs 149.77 crore in the fourth quarter from Rs 135.41 crore in the same period last year.
Amrutanjan Health Care FY2026 net profit increased 13.95 per cent to Rs 57.92 crore, while net sales grew 11.23 per cent to Rs 502.55 crore.
“Our relentless focus on growing the power brands of Amrutanjan and Comfy enabled this growth,” the company said.
“We witnessed growth across the pain management portfolio and especially with LUP packs and premium formats (Roll on, Large packs),” it added.
“We are also actively working to expand width of distribution in new markets and depth in strong markets. We added 44K new chemists and plan to complete the goal of acquiring 100K chemists by September of FY 27,” Amrutanjan said.
“Our new sanitary pad plant is slated to commence production in May and should improve profitability of Comfy brand in the new year,” it said.
